Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
4.630
+0.160 (3.58%)
Feb 4, 2025, 4:00 PM EST - Market closed
Relay Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Relay Therapeutics stock have an average target of 20.11, with a low estimate of 16 and a high estimate of 28. The average target predicts an increase of 334.34% from the current stock price of 4.63.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Relay Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 9 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +245.57% | Jan 14, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $21 | Buy | Reiterates | $21 | +353.56% | Dec 12, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +288.77% | Dec 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $16 | Strong Buy | Maintains | $20 → $16 | +245.57% | Dec 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $19 → $20 | Strong Buy | Maintains | $19 → $20 | +331.97% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
15.85M
from 25.55M
Decreased by -37.95%
Revenue Next Year
3.59M
from 15.85M
Decreased by -77.38%
EPS This Year
-2.57
from -2.79
EPS Next Year
-2.69
from -2.57
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 63.0M | 26.3M | 81.1M | |||
| Avg | 15.9M | 3.6M | 23.1M | |||
| Low | 9.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 146.6% | 65.6% | 2,160.8% | |||
| Avg | -38.0% | -77.4% | 545.4% | |||
| Low | -61.6% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.44 | -2.34 | -1.98 | |||
| Avg | -2.57 | -2.69 | -2.60 | |||
| Low | -2.70 | -3.25 | -3.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.